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ABSTRACT 
A series of new quinazoline derivatives has been recently reported as potent multi-acting his-
tone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and human epidermal 
growth factor receptor 2 (HER2) inhibitors. HER2 is one of the major targets for the treatment 
of breast cancer and other carcinomas. Three-dimensional structure-activity relationship (3D-
QSAR) is a well-known technique, which is used to drug design and development. This tech-
nique is used for quantitatively predicting the interaction between a molecule and the active 
site of a specific target. For each 3D-QSAR study, a three-dimensional model is created from 
a large curve fit to find a fitting between computational descriptors and biological activity. 
This model could be used as a predictive tool in drug design. The best model has the highest 
correlation between theoretical and experimental data. Self-Organizing Molecular Field Anal-
ysis (SOMFA), a grid-based and alignment-dependent 3D-QSAR method, is employed to 
study the correlation between the molecular properties and HER2 inhibitory potency of the 
quinazoline derivatives. Before presentation of inhibitor structures to SOMFA study, confor-
mation of inhibitors was determined by AutoDock4, HyperChem and AutoDock Vina, sepa-
rately. Overall, six independent models were produced and evaluated by the statistical partial 
least square (PLS) analysis. Among the several generated 3D-QSARs, the best model was se-
lected on the basis of its statistical significance and predictive potential. The model derived 
from the superposition of docked conformation with AutoDock Vina with reasonable cross-
validated q2 (0.767), non cross-validated r2 (0.815) and F-test (97.22) values showed a desira-
ble predictive capability. Analysis of SOMFA model could provide some useful information 
in the design of novel HER2 kinase inhibitors with better spectrum of activity. 
 
Keywords: quinazoline, human epidermal growth factor receptor 2, 3D-QSAR, self-
organizing molecular field analysis, AutoDock 
 
 
INTRODUCTION  
The epidermal growth factor receptor 
(EGFR) is the cell-surface receptor of the 
epidermal growth factor family (Herbst, 
2004). This family comprises four structur-
ally related tyrosine kinase receptors, name-
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ly, epidermal growth factor receptor 1 (al-
ternatively named EGFR, ErbB1) or human 
epidermal growth factor receptor 1 (HER1), 
HER2 (ErbB2), HER3 (ErbB3) and HER4 
(ErbB4) (Cho et al., 2003; Satyanarayana-
jois et al., 2009; Woodburn, 1999; Yarden 
et al., 2004). ErbB receptors are made up of 
an extracellular region or ectodomain that 
provides a ligand-binding site, a single 
transmembrane-spanning region, and a cy-
toplasmic tyrosine kinase domain (Garrett 
et al., 2002). When a certain ligand binds to 
the extracellular domain of an ErbB recep-
tor, its dimerization is triggered with other 
adjacent ErbB. There is not any known lig-
and for HER2 and instead this receptor acts 
as a co-receptor for each of the other three 
(Linggi and Carpenter, 2006). Dimerization 
leads to a rapid activation of receptor’s cy-
toplasmic kinase domain (Satyanarayana-
jois et al., 2009). Activated form of the 
ErbB receptors plays a critical role in the 
regulation of cell growth, proliferation and 
migration. Kinase domain subsequently 
catalyzes receptor autophosphorylation and 
tyrosine phosphorylation of ErbB substrates 
(Satyanarayanajois et al., 2009; Pawson, 
1995). It has been shown that HER2 over-
expression is involved in colon, ovarian, 
non-small-lung cell and approximately 25-
30 % of breast cancers (Shmeeda et al, 
2009). Furthermore, amplification content 
is conversely correlated with the observed 
average survival time (Carter et al., 1992).  
Breast cancer is one of the major health 
problems among developed community. It 
is the most common neoplasia among 
women, in which more than 1 million new 
cases occur every year, and it is the first 
cause of death in women aged 40–59 years 
old (Galvao et al., 2011). Just in 2010, 
207,090 new cases are estimated to occur in 
United States with an expected mortality 
rate of 39,840 women (Galvao et al., 2011; 
Jemal et al., 2010). Obstruction of HER2-
mediated multimerization leads to inhibi-
tion of phosphorylation and subsequently, 
uncontrolled cell growth and division will 
limit. So, blocking of HER2-mediated sig-
naling has made it a key target of breast 
cancer therapies (Satyanarayanajois et al., 
2009). Trastuzumab (Herceptin) is an FDA-
approved humanized monoclonal antibody, 
which is used to treat the early stage of 
HER2 overexpressed breast cancer. It binds 
to the ectoplasmic domain of HER2 and 
inhibits any receptor dimerization (Burgess 
et al., 2003). Use of trastuzumab as an ef-
fective drug, because of its cost, is still con-
troversial. In the U.S., 34-week treatments 
for every case (average duration of treat-
ment) costs approximately 23,400 USD 
(Stebbing et al., 2000). Recent studies have 
also shown that cancer treatment by 
trastuzumab may be contributed in one kind 
of drug-induced cardiac dysfunction 
(Zeglinksi et al., 2011). In contrast with 
trastuzumab, chemical new inhibitors like 
erlotinib and lapatinib were designed and 
synthesized against cytoplasmic kinase do-
main of HER2 (Cai et al., 2010). Because 
of high identity and similarity between 
HER2 kinase domain and the other more 
than one hundred kinases in cells, a highly 
specific kinase domain inhibitor is chal-
lenging. On the other side, drug resistance 
could occur due to ATP-binding site muta-
tions (Satyanarayanajois et al., 2009). So, it 
seems that the need to design and synthesis 
of a more potent and specific HER2 kinase 
inhibitor is urgent.  
Quantitative structure-activity relation-
ships (QSAR) have played an influential 
role in the design of pharmaceuticals in 
medicinal chemistry (Akamatsu, 2002). In 
this technique, variation in biological ac-
tivities is statistically analyzed using de-
scriptors related to structural properties of 
compounds. The self-organizing molecular 
field analysis (SOMFA) is a simple three-
dimensional quantitative structure-activity 
relationship (3D-QSAR) technique. In this 
method, the molecular shape and electro-
static potential are used to construct the 
QSAR models (Robinson et al., 1999). Re-
cent study reports the first published crystal 
structure of the kinase domain of HER2, 
which could be a valuable target to design 
the new anti-HER2 drugs (Aertgeerts et al., 
2011). The purpose of this paper is to de-
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scribe the application of molecular docking 
studies and self-organizing molecular field 
analysis, SOMFA, on a series of quinazo-
line derivatives. The worthwhile molecular 
architecture required for designing new 
specific inhibitors against HER2 positive 
breast cancer is also discussed.  
 
MATERIALS AND METHODS 
Overall strategy 
To produce the SOMFA model, mini-
mized and correct geometrical confor-
mations of quinazoline derivatives are 
needed. For this purpose, three independent 
categories of inhibitor conformations were 
produced by AutoDock 4.2 (Morris et al., 
2009), HyperChem 8.0 (Froimowitz, 1993) 
and AutoDock Vina (Trott and Olson, 
2010). For each category, compound 1 was 
selected as the reference compound and the 
other compounds were superimposed by 
atom based alignment technique (Figure 1). 
In this method, superposition of molecules 
is based on trying to minimize root-mean-
squares (RMS) differences in the fitting of 
selected atoms with those of a reference 
molecule (Figure 2). Finally, for each cate-
gory, related SOMFA models were pro-
duced by SOMFA software (Figure 3) 
(Robinson et al., 1999).  
*
*N
*R2
R1
NH
R3
 
Figure 1: Atoms used for atom based align-
ment are specified by an asterisk data set. 
 
Figure 2: Superposition of all structures on ref-
erence compound. For ease of visualization, 
hydrogen atoms are not shown.  
 
Figure 3: Flow chart of 3D-QSAR modeling procedure which is used in this study. Based on molecular 
docking and modeling software and SOMFA resolution utilized, for each category two models were 
generated. Models A1, B1 and C1 have resolution 1, whereas, resolution of 0.5 was assigned for 
model A2, B2 and C2. 
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In this study, a data set of 24 compounds 
belonging to the quinazoline derivatives as 
HER2 inhibitors were taken from the litera-
ture (Cai et al., 2010) and used to produce 
SOMFA model (Table 1). The chemical 
structures of mentioned compounds were 
generated by PRODRG server (Schuttel-
kopf and van Aalten, 2004). For optimiza-
tion of constructed compounds, molecular 
mechanic (MM+) optimization followed by 
the semi-empirical AM1 (Austin Model 1) 
method implemented in HyperChem soft-
ware were used. For both the above men-
tioned methods, molecular structures were 
optimized using the Polak-Ribiere (conju-
gate gradient) algorithm until the root mean 
square (RMS) gradient achieves a value 
smaller than 0.001 kcal mol-1.  
 
Table 1: Structural and activity data of the 
quinazoline derivatives studied (Cai et al., 
2010) 
 
N
N
O
O
NH
R1
R2
O
N
H
OH n
 
 
Com-
pound n R1 R2 
IC50 
(nM) in  
enzyme 
assay* 
1 1 F Cl 10.6 
2 2 F Cl 12.4 
3 3 F Cl 15 
4 3 H C CH 38.4 
5 4 F Cl 20 
6 4 H C CH 38.2 
7 5 F Cl 19 
8 5 H C CH 15.7 
9 5 F C CH 76.5 
10 5 
F
O
 
Cl 10.1 
erlotinib    134.5 
lapatinib    10.2 
N
N
NH
F
Cl
R3
XN
H
OH
O
 
Compound X R3 
IC50 
(nM) in 
enzyme 
assay* 
11 O H- 43.5 
12 O CH3OCH2CH2O- 24 
13 CONH CH3O- 20.1 
14 S CH3O- 24.2 
N
N
NH
X
O
N
H
OH
O
Y R1
R2
 
Compound Y R1 R2 
IC50 
(nM) in 
enzyme 
assay*  
15 CH2 F Cl 478.2 
16 CH2 H H 225.2 
17 CH2 F H 295.4 
18 (R)-CHCH3 H H 27.8 
19 (R)-CHCH3 F H 175 
20 (R)-CHCH3 Cl H 556.9 
N
N
NH
R1
R2
O
ON
O
OH
 
Compound R1 R2 
IC50 (nM) in 
enzyme assay* 
21 F Cl 478.2 
22 H C CH  225.2 
*enzyme assay was performed by HTScan® 
HER2/ErbB2 Kinase Assay Kit. 
 
Biological activity 
The negative logarithm of the measured 
IC50 (M) against human HER2 kinase do-
main as pIC50 was used as dependent varia-
ble (Cai et al., 2010). HER2 kinase activity 
was measured using HTScan® HER2/ 
ErbB2 Kinase Assay Kit (Cell Signaling 
Technology). It includes active HER2/ 
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ErbB2 kinase (supplied as a GST fusion 
protein), a biotinylated peptide substrate 
and a phospho-tyrosine antibody for detec-
tion of the phosphorylated form of the sub-
strate peptide. The enzyme assay was per-
formed based on fluorescent immuno-de-
tection approach (Cai et al., 2010). 
 
Protein preparation 
3D crystallographic structure of  the ki-
nase domain of human HER2 (ErbB2) with 
PDB code 3PPO (Aertgeerts et al., 2011) 
was obtained from the Brookhaven protein 
data bank (Berman et al., 2000). For use of 
kinase domain structure in docking simula-
tion, all missing hydrogen atoms were add-
ed by Hbuild command implemented in 
CHARMM molecular dynamic package 
(Brooks et al., 2009). All water molecules 
were eliminated except for water ID 22, 
which is tightly bounded to the active site 
of HER2 kinase domain. After initial mini-
mization by Adopted Basis Newton-
Raphson (ABNR) and steepest descent 
(SD) methods, output structure was saved 
and used for molecular docking studies.  
 
Molecular docking studies 
AutoDock 4.2 
Autodock is a flexible docking tech-
nique which is based on Monte Carlo simu-
lated annealing search to find the optimal 
conformation of ligand in a macromolecule. 
Inhibitor structures minimized by Hyper-
Chem were used as input ligand files for 
AutoDock 4.2. Ligand preparation was 
done by AutoDockTools. The grid maps 
were calculated using AutoGrid (part of the 
AutoDock package). Because the active site 
of HER2 kinase domain is known 
(Aertgeerts et al., 2011), a grid map with 25 
× 25 × 25 points with a grid-point spacing 
of 1 Å (roughly a quarter of the length of a 
carbon-carbon single bond) were defined. 
For both protein and ligands, the partial 
atomic charges were calculated using the 
Gasteiger-Marsili method (Gasteiger and 
Marsili, 1980). For all dockings, 50 inde-
pendent runs with the step sizes of 0.2 Å for 
translations and 5° for orientations and tor-
sions were performed. For each ligand, 
pose with the minimum free energy of bind-
ing was saved and used for SOMFA study.  
 
AutoDock Vina 
AutoDock Vina is a molecular docking 
software that profits of knowledge-based 
potentials and empirical scoring functions 
(Trott and Olson, 2010). Minimized inhibi-
tor structures were defined as input files for 
AutoDock Vina. The docking site for inhib-
itors on 3PPO was defined by setting up a 
box with a grid map with 25 × 25 × 25 
points (grid-point spacing of 1 Å) at the ge-
ometrical center of the native ligand present 
in PDB structure. Software parameter "Ex-
haustiveness", which determines how com-
prehensively the program searches for the 
lowest energy conformation, was set to the 
default value, eight for all docking runs. For 
each docking calculation, structure with 
relative binding energy, based on the soft-
ware cluster, was saved and employed to 
SOMFA study.  
 
SOMFA 3D-QSAR study 
To produce a 3D-QSAR model, SOM-
FA2 package software was used. This suite 
of programs is designed to enable the user 
to carry out an advanced 3D-QSAR analy-
sis of a series of molecules. The results of 
the analysis enable the rationalization of the 
activities of known molecules together with 
the potential for reliably estimating the ac-
tivity of molecules that have yet to be syn-
thesized (Robinson et al., 1999). In our 
SOMFA study, a 40 × 40 × 40 Å grid origi-
nating at (-20, -20, -20) with a two resolu-
tion (1 and 0.5 Å) were generated around 
the aligned compounds. 
Six different models using different res-
olutions and aligned conformations of in-
hibitors have been produced and presented 
in Table 2. For all the studies, shape and 
electrostatic potential were produced as an 
independent variable. These two variables, 
consequently, combined to create the final 
model by utilizing the partial least square 
(PLS) algorithm in conjugation with leave 
one out (LOO) cross-validation method. 
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Based on equation 1, weighted average of 
shape and electrostatic were calculated: 
Activity = c1 Activityshape  + (1 - c1) Activi-
tyESP (1) 
where c1 is a mixing coefficient.  
The predictive ability of the model is 
quantitated in terms of q2 (r2cv) which is de-
fined in equation 2: 
q2 = 1 – PRESS/SSD (2) 
where SSD is the sum of squared devia-
tions between observed values and the 
mean of predicted property values. PRESS 
is the sum of squared deviations between 
observed and predicted property values: 
PRESS = ∑ (Yobserved – Ypredicted) 
q2 takes up values in the range from 1 to 
less than 0. Low or negative values of q2 
indicate the errors of prediction are greater 
than the error from assigning each com-
pound mean activity of the model. Higher 
values of q2  is necessary but not sufficient 
for evaluating a QSAR model (Golbraikh 
and Tropsha, 2002). One of the several var-
iance-related parameters that can be used as 
a criterion of the level of statistical signifi-
cance of the regression model is Fischer 
statistic parameter (F-value). The larger 
value of F implies that a more significant 
correlation has been reached (Kulkarni et 
al., 1999). Because the final equations are 
not very useful to efficiently denote the 
SOMFA models, 3D master grid maps of 
the best models are displayed by Grid-
Visualizer program. These grids represent 
an area in space where steric and electro-
static field interactions are responsible for 
the observed variations of the biological 
activity.  
 
RESULTS AND DISCUSSION 
Numerous small organic compounds 
have been synthesized and evaluated as in-
hibitors of EGFR and HER2 tyrosine kinas-
es (Traxler et al., 1997; de Bono and 
Rowinsky, 2002). Since, quinazoline deriv-
atives could inhibit the HER2 and account 
for potent HER2/EGFR inhibitors (Cai et 
al., 2010), 3D quantitative structure activity 
relationship study with aid of molecular 
docking method was done to develop more 
influential HER2/EGFR mediated anti-
cancer drugs. In the first phase of this 
study, to ensure the docking protocol is set 
up correctly; an internal validation phase 
was done.  
 
 
 
 
Table 2: Statistical characteristics of the 3D QSAR models for selectivity 
Model Modeling  software* Resolution r
2 s F c1 c2 q2 r 
A1 AutoDock4 1 0.722 0.289 56.999 0.7 0.3 0.685 0.849 
A2 AutoDock4 0.5 0.702 0.3 51.745 0.7 0.3 0.658 0.838 
B1 HyperChem 1 0.731 0.284 59.931 0.7 0.3 0.697 0.855 
B2 HyperChem 0.5 0.722 0.289 57.124 0.7 0.3 0.686 0.850 
C1 AutoDock Vina 1 0.813 0.237 95.838 0.6 0.4 0.765 0.902 
C2 AutoDock Vina 0.5 0.815 0.236 97.22 0.6 0.4 0.767 0.903 
*Modeling software which is used to produce the initial conformation of inhibitors as input files in 
SOMFA.  
Resolution, utilized grid spacing in SOMFA software; r2, Non cross-validated correlation coefficient; s, 
standard error of estimate; F, F-test value; c1 and c2, mixing coefficient of SOMFA model; q2, Cross-
validated correlation coefficient; r, correlation coefficient. A model with high r2, q2 and F-test values 
was selected as the best model. It should be noted that a high q2 is only a necessary but not sufficient 
condition for a good prediction. 
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Internal validation phases  
In this phase, SYR127063, which is the 
reference ligand of the crystal structure 
with PDB code 3PPO, was docked by Au-
toDock 4 and AutoDock Vina, separately 
(Aertgeerts et al., 2011). Superimposing the 
experimental and predicted conformations 
was expressed as root mean square devia-
tion (RMSD). Calculated RMSD for 
SYR127063 were 3.56 and 0.65 Å for Au-
toDock4 and AutoDock Vina, respectively. 
The results showed that the molecular 
docking method by AutoDock Vina is ro-
bust and suitable for estimating the interac-
tions of such ligand with kinase domain of 
HER2. Conversely, computed RMSD of 
3.56 is accepted as poor docking method. 
Figure 4 shows the similarity between ex-
perimental and docked structures by two 
docking methods.  
 
 
Figure 4a 
 
Figure 4: Cartoon view of the active pocket of 
kinase domain of HER2 with its ligand 
(a) Superposition of the docked structure and 
the crystal structure of SYR127063 which is 
calculated by AutoDock4 
 
 
Figure 4b 
(b) Superposition of the docked structure and 
the crystal structure of SYR127063 which is 
computed by AutoDock Vina. The crystal struc-
ture and docked conformation of SYR127063 
are shown by red and green colors, respective-
ly. For ease of visualization, hydrogen atoms 
are neglected. 
 
 
Models produced by 3D-QSAR  
In this section, as mentioned prior, six 
models were produced based on initial co-
ordination of inhibitors. For predicted mod-
els, cross-validated r2 or q2 and also F-
values were computed and served as a 
quantitative measure of the predictability of 
the SOMFA models. Statistical analyses of 
models are summarized in Table 2. Poor 
models are belonging to model A1 and A2 
with the minimum values of q2 and high 
quantity of standard error. As shown in 
Figure 4, the RMSD between docked and 
crystal structure is high, and it’s not ac-
ceptable as a successful docking in molecu-
lar modeling studies. So, it can be postulat-
ed that the conformation of models, which 
are calculated by AutoDock4 have lower 
validity. When the three-dimensional struc-
ture of macromolecule target is not deter-
mined, or if it has not an acceptable resolu-
tion, or also when a critical amino acid of 
target active site is missed, use of semi-
empirical methods to calculate the initial 
coordination in the 3D-QSAR study is 
common. Some studies apply this method 
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instead of molecular docking (Rajwade and 
Pande, 2008; Aggarwal et al., 2010). Model 
B1 and B2 have higher values of q2. The 
minimization of structures of these models 
was done by HyperChem. Among all of 
models, the best one which is predicted by 
using of AutoDock Vina and SOMFA 
software was C2. The mentioned model 
which has q2 value of 0.76, r2 value of 0.8, 
minimum standard error of 0.23 and F-test 
value of 97.22, demonstrates a satisfying 
statistical correlation and predictive ability. 
Based on our results, the models with the 
initial structures docked by AutoDock Vina 
are the best and those docked with Auto-
Dock4 are poor and models B1 and B2 are 
moderate in view of validity. In molecular 
docking software, three parameters deter-
mine the success of docking study. The first 
is ligand and macromolecule representation, 
which is same in both AutoDock4 and Vi-
na. Second is the scoring function of dock-
ing software. AutoDock4 uses five terms, 
including van der Waals, electrostatic, hy-
drogen bond, torsional penalty and desolva-
tion parameter as its scoring function 
(Morris et al., 2009; Chang et al., 2010). 
Instead, AutoDock Vina employs just three 
score function terms comprising hydropho-
bic interaction (van der Waals), hydrogen 
bond and torsional penalty (Trott and 
Olson, 2010). Although, the above-
mentioned docking packages use the same 
empirically-weighted scoring functions, but 
they have different empirical parameters 
and thereby, have a distinctive calculation. 
The third item that affects docking validity 
is the search algorithm. With regard to Fig-
ure 4 and Table 2, it seems that stochastic 
search algorithm of AutoDock4 has a poor 
function and efficiency compared to Vina. 
AutoDock Vina optimizes its local search 
application by calculation of derivatives of 
any ligand conformation energy, which is 
known as the gradient-based local search 
algorithm. Such method could increase 
speed and accuracy in AutoDock Vina. 
Trott and Olson (2010) showed that in re-
docking of 190 protein-ligand complexes 
with RMSD tolerance of 2 Å, success per-
centage of AutoDock4 and Vina was 49 % 
and 78 %, respectively (Trott and Olson, 
2010). Statistical analysis of our data and 
also the calculated RMSD of SYR127063 
in validation phase confirm such conclu-
sion. In the course of SOMFA study, grid 
spacings of 1 and 0.5 Å were examined. 
Our data showed that in comparison with 
1 Å, the 0.5 Å grid spacing generates a 
model with a good correlation (Table 2). 
For the other models, it seems that 1 Å grid 
spacing is suitable. It can be postulated if 
the structures with wrong or far from native 
conformation are used for grid-based 3D-
QSAR, with decreasing of grid spacings, 
the amount of noise in the descriptor data is 
increased. Therefore, the quality of the 
model is reduced. In model C2, which has 
the best correlation with experimental data, 
the biological and predicted activities of the 
training and test sets are presented in Table 
3. Figure 5 is depicted based on Table 3 and 
shows a good correlation (r2= 0.81) be-
tween biological and predicted activity of 
HER2 inhibitors. Figure 6 shows the plot of 
the predicted versus biological activity val-
ues of test set, demonstrating that the most 
compounds are predicted satisfactorily.  
 
 
Figure 5: Predicted versus biological activity of 
data set from the best predictive SOMFA model 
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Table 3: Biological and predicted activities of 
training and test sets from the Model C2  
Compound 
Biological 
activity 
(pIC50)* 
Predicted 
activity 
Residual 
activity 
1 7.970 7.636 0.334 
2 7.900 7.684 0.216 
3 7.820 7.709 0.111 
4 7.410 7.133 0.277 
5 7.690 7.756 -0.066 
6 7.410 7.625 -0.215 
7 7.720 7.764 -0.044 
8 7.800 7.659 0.141 
9 7.110 7.397 -0.287 
10 7.990 7.970 0.020 
11T 7.360 7.264 0.096 
12T 7.610 7.511 0.099 
13T 7.690 7.433 0.257 
14T 7.610 7.814 -0.204 
15 6.320 6.216 0.104 
16 6.640 6.486 0.154 
17 6.520 6.760 -0.240 
18 7.550 7.465 0.085 
19 6.750 7.478 -0.728 
20 6.250 6.338 -0.088 
21 7.140 7.119 0.021 
22 7.280 7.191 0.089 
erlotinibT 6.870 7.081 -0.211 
lapatinib 7.990 7.910 0.080 
T: test set molecules 
*negative logarithm of IC50, which is measured 
by HTScan® HER2/ErbB2 Kinase Assay Kit 
(Cai et al., 2010). 
 
 
Figure 6: Predicted versus biological activity of 
test set from the best predictive SOMFA model  
Electrostatic and shape contribution in 
SOMFA model 
SOMFA produces a model based on 
shape and electrostatic independent varia-
bles. Shape values are given a value of 1 
inside the van der Waals envelope and 0 for 
outside. Electrostatic values calculated by 
use of the partial charges distributed across 
the atom centers (Robinson et al., 1999) the 
SOMFA models. The models that have 
been produced using AutoDock 4 or Vina, 
electrostatic contribution was decreased to 
0, by use of Gasteiger charge (data not 
shown). However, by assigning the AM1 
charge as a partial atom charge, this propor-
tion was raised. The same deduction was 
presented by Li et al. (2011). It has been 
shown that the partial charge computation 
method can affect the validity of 3D-QSAR 
models in a statistically significant mode 
(Mittal et al., 2009). AM1 charges are a set 
of Mulliken-type charges derived from a 
semi-empirical quantum-mechanical calcu-
lation (Mittal et al., 2009). Semi-empirical 
quantum methods are a mediocre between 
the empirical and ab initio quantum chemi-
cal approaches in terms of accuracy and 
computational time. Instead, Gasteiger 
charge calculation is an empirical atomic 
partial charge method which utilizes exper-
imental parameters of its data set (Gasteiger 
and Marsili, 1980). One of the reasons for 
superiority of AM1 than Gasteiger atomic 
charge method is that AM1 embeds some 
quantum mechanic equations, which help to 
calculate a more accurate atomic charge 
than Gasteiger procedure. Mittal et al. 
(2009) concluded that semi-empirical 
charges give better predictive certain 3D-
QSAR models than using Gasteiger partial 
charge calculation methods. The second 
reason is that in molecular docking meth-
ods, which are based on AutoDock4 or Vi-
na, just polar hydrogen atoms are assigned. 
So, partial atomic charges were not calcu-
lated for non-polar hydrogen atoms. It 
might affect the final SOMFA model and 
cause a negative deviation in computation 
of electrostatic contribution. The both elec-
trostatic and shape potentials of the model 
EXCLI Journal 2013;12:130-143 – ISSN 1611-2156 
Received: January 24, 2013, accepted: February 16, 2013, published: February 22, 2013 
 
139 
C2 were computed. The contribution of 
electrostatic field and shape field to QSAR 
equation is 40 % and 70 %, respectively. 
Our SOMFA analysis result indicates that 
the shape contribution is of higher im-
portance than the electrostatic one.  
 
SOMFA model and HER2 active site 
analysis  
The SOMFA shape potential for the 
analysis is presented as master grid in Fig-
ure 7. In this figure, structure of compound 
1 is shown as reference compound. Red 
spots indicate that steric bulk enhances ac-
tivity in this region. Contrariwise, cyan 
spots show that steric bulk detracts from 
activity in this region. Favorable and unfa-
vorable electrostatic regions are depicted in 
Figure 8. In this figure, red spots indicate 
that positive charge is favored in this re-
gion. Alternatively, negative charge is dis-
favored in this region. Cyan spots demon-
strate that negative charge is favored in this 
region. In other words, positive charge is 
disfavored in this region. Based on Figure 
7, ring substitution in the position R1 and R2 
in compounds 1-10 can moderately affect 
the HER2 inhibitory potency. Compound 1 
has two bulky chlorine and fluorine on its 
phenyl ring, which could make a hydropho-
bic interaction with Val 734, Thr 798, Ala 
751, Leu 852 and Leu 726 (Figure 9). 
Since, water ID 22 acts as a portion of the 
active site of HER2 and it’s essential for 
catalysis (Aertgeerts et al., 2011), it was 
assigned in molecular docking studies. 
Based on Figure 9, hydrogen bond is 
formed between compound 1 and water ID 
22. The most potent compound (compound 
10) has the minimum IC50. The bulky 
fluorobenzene moiety could interact with 
Leu 785, Thr 798, Val 734 and Leu 852 via 
hydrophobic interaction (Figure 10). These 
amino acids form a hydrophobic pocket that 
fluorobenzene moiety could lie on it. This 
hydrophobic moiety decreases the IC50, 
which is in accordance with our shape 
SOMFA model (Figure 7). Based on Figure 
7, number of carbons in the hydrocarbon 
tail might affect the HER2 kinase inhibitory 
potency. Although, compound 1 with n=1 
(number of carbon in the hydroxamic tail) 
has an IC50 equal to 10.6, but it seems that 
optimal n is 5 (Cai et al., 2010). Hydrocar-
bon tail (n=5) of hydroxamic acid lets this 
moiety to form a hydrogen bond with Arg 
849 and Asp 863. NH of Met 801, which is 
an important amino acid in HER2 active 
site (Aertgeerts et al., 2011), makes a hy-
drogen bond with one of the adenine moiety 
nitrogens. The remaining nitrogen also 
forms a hydrogen bond with water 22. With 
regard to Figure 7, C-7 substitution (R3) 
with long chain at quinazoline ring can re-
duce the inhibitory activities. High IC50 of 
compounds 21 and 22 (478.2 for compound 
22 and 225.2 for compound 22) correlate 
with our results (Cai et al., 2010). Figure 11 
shows the 2-dimensional position of com-
pound 22 in HER2 kinase active site. In 
spite of the fact that compound 22 contrib-
utes in several hydrogen bonds, polar Lys 
753 with the positive charges in position 
with hydrocarbon tail might decrease the 
HER2 inhibitory potency. Furthermore, be-
cause of the long chain in compounds 21 
and 22, conformational change of chloro-
flourophenyl moiety could not let this 
group interact with any non-polar residues 
via hydrophobic interaction. Our data 
shows that hydrophobic interaction of the 
moiety mentioned above could influentially 
increase the HER2 inhibitory potency. Ta-
ble 1 shows that addition of a bulky group 
in position R1, R2 and Y simultaneously 
leads to decrease in HER2 inhibitory activi-
ty. Compound 20 has chlorine in position 
R1 and ethyl in position Y. IC50 of this 
compound is 556.9. With exchange of chlo-
rine with fluorine, IC50 was sharply de-
creased (compound 19). Compound 15 pos-
sesses CH2 in position Y and fluorine and 
chlorine in positions R1 and R2, respective-
ly. IC50 of this compound is slightly lesser 
than that of compound 20. Based on our 
SOMFA model (Figure 7), phenyl moiety 
of compounds 15, 16 and 20 are located on 
cyan spots area. These results have a good 
agreement with experimentally obtained 
IC50 values (Cai et al., 2010).  
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Figure 7: The shape potential master grid of 
model C2 with compound 1. Red spots portray 
areas of desirable steric interactions. Blue spots 
represent areas of undesirable steric interac-
tions. 
 
 
Figure 8: The electrostatic potential master grid 
of model C2 with compound 1. Red portrays 
areas where positive potential is favorable, or 
negative charge is unfavorable. Blue demon-
strates areas where negative potential is desir-
able, or positive charge is undesirable. 
 
 
Figure 9: Schematic two-dimensional represen-
tations of the binding interactions between 
compound 1 and active site of HER2 kinase 
domain. Black dashed lines are hydrogen 
bonds. Hydrophobic interactions are shown by 
solid line green. HOH22W represents water 
molecule. 
 
Figure 10: Schematic two-dimensional repre-
sentations of the binding interactions between 
compound 10 and active site of HER2 kinase 
domain. Black dashed lines are hydrogen 
bonds. Hydrophobic interactions are shown by 
solid line green. HOH22W represents water 
molecule. 
Figure 11: Schematic two-dimensional repre-
sentations of the binding interactions between 
compound 22 and active site of HER2 kinase 
domain. Black dashed lines are hydrogen 
bonds. Hydrophobic interactions are shown by 
solid line green. HOH22W represents water 
molecule. 
 
 
The authors suggest that based on 
SOMFA analysis presented in this study, 
more potent inhibitors of kinase domain of 
HER2 could be designed and synthesized.  
 
CONCLUSION 
In the last decade, structure-based 
methods have become great tools in drug 
design, including lead discovery and opti-
mization. It has also been shown that struc-
ture-based methods are now able to predict, 
with an acceptable degree of exactness, the 
position of a ligand in its binding site. 
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Combining the molecular docking and 3D-
QSAR studies could be employed to design 
the more potent HER2 chemical inhibitors. 
By the aid of molecular docking, the de-
rived 3D-QSAR models are also able to in-
dicate which interaction sites in the binding 
pocket might be responsible for the vari-
ance in biological activities. Active site 
analysis of kinase domain of HER2 also lets 
us interpret and validate our QSAR model. 
In this study, calculated SOMFA 3D-QSAR 
models for quinazoline derivatives were 
expanded. Because of the nature of HER2 
active site, which is covered by hydropho-
bic residues, shape contribution in our 
SOMFA model is a dominant factor. The 
number of hydrophobic interactions and 
hydrogen bonding between chemical inhibi-
tors and HER2 active site could increase the 
inhibitory potency. These features provide 
some useful information that might be used 
in new quinazoline derivatives with a high 
and influential HER2 inhibitory activity.  
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